On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy (FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits bromodomain… Read More »
Q &A on potential use of BET inhibitors for FSHD
Johns Hopkins Studies
Johns Hopkins and the Kennedy Krieger Institute are currently recruiting for two studies! Volunteering for studies like this helps provide researchers with the information they need to provide better treatments,… Read More »
Imaging study shows positive effects of exercise and CBT on muscle degeneration
In 2014, a Dutch team reported that aerobic exercise training (AET) and cognitive behavioral therapy (CBT) decreased fatigue and improved the quality of life significantly in FSHD patients. Now, the… Read More »
Consensus Reached to Move Forward with Formation of International Global FSHD Patient Registry
Newly Formed Facioscapulohumeral Muscular Dystrophy Consortium Aims to Consolidate More than 13 Patient Registries in Effort to Accelerate Research on Rare Disease BOSTON – (February 22, 2017) – Today the… Read More »
Promising FSHD mouse model from Harper lab
Video caption: These mice are siblings and genetically identical. In the one on the right, we turned DUX4 “on”, while in the one on the left, the DUX4 gene remained… Read More »